EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer

Mike Wenzel, Benedikt Hoeh, Clara Humke, Cristina Cano Garcia, Carolin Siech, Thomas Steuber, Markus Graefen, Miriam Traumann, Luis Kluth, Felix K H Chun, Philipp Mandel

World Journal of Urology · 2024

DOI: 10.1007/s00345-024-05388-1 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift World Journal of Urology, 2024. Verfasst von Mike Wenzel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Mike.Wenzel@unimedizin-ffm.de. Hauptthemen laut MEDLINE: Docetaxel, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Frankfurt.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

No currently available phase III trial compared docetaxel vs. androgen receptor pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Moreover, few is known about the effect of sequential therapies in mHSPC and subsequent metastatic castration resistant prostate cancer (mCRPC).

Methods

We relied on the FRAMCAP database and compared docetaxel vs. ARPI in mHSPC patients regarding time to mCRPC (ttCRPC) and overall survival (OS). Sensitivity analyses addressed high volume mHSPC patients. Finally, sequential therapies were compared regarding progression-free survival (PFS) and OS in first-line mCRPC.

Results

Of 419 included mHSPC patients, 25% received docetaxel vs. 75% ARPI. ARPI patients were significantly older (71 vs. 66 years), and harbored lower baseline PSA (38 vs. 183 ng/ml, both p ≤ 0.002). Median ttCRPC was significantly longer for ARPI than for docetaxel-treated patients (30 vs. 17 months, hazard ratio [HR]: 0.49, p < 0.001). In OS analyses, ARPI patients also exhibited significantly longer OS, relative to docetaxel patients (96 vs. 50 months, HR: 0.67, p = 0.03). After multivariable adjustment in Cox regression models, no difference between both treatments remained in both analyses (all p > 0.05). In sensitivity analyses of high volume mHSPC patients only, also no ttCRPC or OS differences were observed for ARPI vs. docetaxel (all p > 0.05). Regarding sequential therapies, no PFS and OS differences were observed for all and specifically high volume mHSPC patients, when ARPI-ARPI vs. ARPI-docetaxel vs. docetaxel-ARPI treatments were compared (all p > 0.05).

Conclusion

In real-world setting, ARPI treatment performs comparable to docetaxel chemotherapy in mHSPC. Therefore, docetaxel should only be used in triplet therapy. Moreover, no differences for sequential therapies of ARPI/docetaxel combinations in first-line mCRPC were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DocetaxelProstatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsHumansMaleAgedMiddle AgedAntineoplastic AgentsRetrospective StudiesSurvival RateNeoplasm Metastasis

Stichwörter der Autor:innen

ARPIApalutamideEnzalutamidemCRPC, high volumemHSPC

Substanzen

DocetaxelAndrogen Receptor AntagonistsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany. Mike.Wenzel@unimedizin-ffm.de.
  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.

Förderung

  • Universitätsklinikum Frankfurt

Zitieren

APA

Wenzel, M., Hoeh, B., Humke, C., Cano Garcia, C., Siech, C., Steuber, T., Graefen, M., Traumann, M., Kluth, L., Chun, F. K. H., & Mandel, P. (2024). Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer. World Journal of Urology. https://doi.org/10.1007/s00345-024-05388-1

Vancouver

Wenzel M, Hoeh B, Humke C, Cano Garcia C, Siech C, Steuber T, et al. Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer. World Journal of Urology. 2024. doi:10.1007/s00345-024-05388-1

BibTeX
@article{Wenzel2024,
  author = {Wenzel, Mike and Hoeh, Benedikt and Humke, Clara and Cano Garcia, Cristina and Siech, Carolin and Steuber, Thomas and Graefen, Markus and Traumann, Miriam and Kluth, Luis and Chun, Felix K H and Mandel, Philipp},
  title = {Androgen receptor pathway inhibitors vs. docetaxel chemotherapy for metastatic hormone-sensitive and first-line castration resistant prostate cancer},
  journal = {World Journal of Urology},
  year = {2024},
  doi = {10.1007/s00345-024-05388-1}
}
Kostenlos starten →